唑来膦酸联合化疗治疗肺癌骨转移的临床疗效观察

摘要

Objective:To investigate the clinical efficacy of Zoledronic Acid combined with chemotherapy in the treatment of bone metastasis of lung cancer.Method:68 cases of lung cancer patients with bone metastasis meeting the inclusion critera were randomly divided into two groups,34 cases in each group.The control group was treated with Zoledronic Acid combined with chemotherapy and the observation group was treated with Zoledronic Acid on the basis of treatment of the control group.The curative efficacy and remission rates of bone metastases of two groups were observed and compared.Result:The effective rate of pain relief in the observation group was 94.12%,and in the control group was 76.47%,the curative efficacy between two groups was significantly different(P<0.05). The remission rate of bone metastases in the observation group was 91.18%,and the control group was 70.59%,the observation group were significantly higher than that of the control group(P<0.05).Conclusion:Zoledronic Acid combined with chemotherapy in the treatment of bone metastasis of lung cancer can effectively reduce the degree of patients’pain,and it is well tolerated,it could be largely improved the quality of life of patients and it will be worthy of further application and promotion.%目的：探讨唑来膦酸联合化疗治疗肺癌骨转移的临床疗效。方法：选取2012年8月-2014年8月笔者所在医院收治的肺癌骨转移患者68例，采用随机数字表法分为观察组与对照组，每组34例，观察组患者应用唑来膦酸联合化疗治疗，对照组患者仅单纯应用唑来膦酸治疗，对比两组临床疗效和骨转移灶缓解率。结果：观察组患者疼痛缓解有效率为94.12%，对照组为76.47%，观察组明显优于对照组，差异有统计学意义(P<0.05)；观察组患者骨转移灶缓解率为91.18%，对照组为70.59%，观察组明显高于对照组，差异有统计学意义(P<0.05)。结论：唑来膦酸联合化疗治疗肺癌骨转移可有效降低患者的疼痛程度，且耐受性较好，能很大程度将患者生活质量提高，值得临床进一步应用及推广。